Patient characteristics according to CBF subtype
| . | t(8;21) AML . | inv(16)/t(16;16) . | P value . |
|---|---|---|---|
| Patients, n | 96 | 102 | |
| Treatment arm (A/B), n | 48/48 | 52/50 | .99 |
| Median age, y (range) | 42 (18-60) | 42 (18-60) | .37 |
| Gender (male/female), n | 54/42 | 52/50 | .48 |
| Median WBC, 109/L (range) | 11.0 (0.7-94) | 22.0 (1-254) | <.001 |
| Median BM blasts, % (range) | 52 (9-98) | 57 (21-92) | .10 |
| Median fusion transcript ratio, % (range) | 303 (34-1090) | 88 (23-549) | <.001 |
| Secondary AML | 10 | 3 | .044 |
| CNS involvement | 3 | 1 | .36 |
| Additional cytogenetic abnormalities, n* | |||
| Loss of Y | 33 | 0 | <.001 |
| Trisomy 8 | 2 | 15 | .002 |
| Trisomy 22 | 0 | 18 | <.001 |
| del(9q) | 14 | 1 | <.001 |
| del(7q)/-7 | 4 | 5 | .99 |
| Gene mutations, n† | |||
| KIT exon 8 | 6 | 12 | .22 |
| KIT exon 17 | 17 | 6 | .013 |
| KIT, all | 22 | 18 | .37 |
| FLT3-TKD | 4 | 16 | .009 |
| FLT3-ITD | 6 | 5 | .76 |
| FLT3, all | 10 | 20 | .11 |
| RTK, all | 30 | 36 | .65 |
| N-RAS | 13 | 28 | .022 |
| K-RAS | 2 | 11 | .02 |
| RAS, all | 15 | 39 | .001 |
| . | t(8;21) AML . | inv(16)/t(16;16) . | P value . |
|---|---|---|---|
| Patients, n | 96 | 102 | |
| Treatment arm (A/B), n | 48/48 | 52/50 | .99 |
| Median age, y (range) | 42 (18-60) | 42 (18-60) | .37 |
| Gender (male/female), n | 54/42 | 52/50 | .48 |
| Median WBC, 109/L (range) | 11.0 (0.7-94) | 22.0 (1-254) | <.001 |
| Median BM blasts, % (range) | 52 (9-98) | 57 (21-92) | .10 |
| Median fusion transcript ratio, % (range) | 303 (34-1090) | 88 (23-549) | <.001 |
| Secondary AML | 10 | 3 | .044 |
| CNS involvement | 3 | 1 | .36 |
| Additional cytogenetic abnormalities, n* | |||
| Loss of Y | 33 | 0 | <.001 |
| Trisomy 8 | 2 | 15 | .002 |
| Trisomy 22 | 0 | 18 | <.001 |
| del(9q) | 14 | 1 | <.001 |
| del(7q)/-7 | 4 | 5 | .99 |
| Gene mutations, n† | |||
| KIT exon 8 | 6 | 12 | .22 |
| KIT exon 17 | 17 | 6 | .013 |
| KIT, all | 22 | 18 | .37 |
| FLT3-TKD | 4 | 16 | .009 |
| FLT3-ITD | 6 | 5 | .76 |
| FLT3, all | 10 | 20 | .11 |
| RTK, all | 30 | 36 | .65 |
| N-RAS | 13 | 28 | .022 |
| K-RAS | 2 | 11 | .02 |
| RAS, all | 15 | 39 | .001 |
RTK, receptor tyrosine kinase (KIT and/or FLT3).
A total of 196 the 198 patients, including 96 t(8;21) and 101 inv(16)/t(16;16) AML patients, had an available karyotype.
A total of 194 of the 198 patients, including 93 t(8;21) and 101 inv(16)/t(16;16) AML patients, were tested for KIT, FLT3 and RAS mutations.